Dallas' Secretome Therapeutics Appoints Board Director, Assembles Clinical Advisory Board

Secretome Therapeutics, a Dallas-based biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells, has appointed Margot Connor to its board of directors and announced the appointment of its clinical advisory board composed of world-class clinicians and researchers in the field of heart failure.

“I have been fortunate to be part of the stem cell-based therapy evolution, and I believe secretomes are a true breakthrough in this extraordinary field,” Connor said in a statement. “Secretome Therapeutics’ team, vision, and groundbreaking products have the potential to revolutionize treatment for a wide range of chronic, inflammatory diseases, and I am thrilled to join the company’s Board.”

The new Clinical Advisory Board members include:

Javed Butler, MD, President, Baylor, Scott and White Research Institute and Member, FDA Cardio-Renal Advisory Committee
Barry Greenberg, MD, Director of the Advanced Heart Failure Treatment Program, and Distinguished Professor of Medicine at U.C. San Diego
Steven Lipshultz, MD, Professor of Pediatrics at the University at Buffalo Jacobs School of Medicine & Biomedical Sciences and Principal Investigator of the North American Pediatric Cardiomyopathy Registry
Arshed Quyyumi, MD, Professor of Medicine, Director of the Emory Clinical Cardiovascular Research Institute
Sanjiv Shah, MD, Professor of Medicine, Founder and Director of the Heart Failure with Preserved Ejection Fraction (HFpEF) Program at the Northwestern University Feinberg School of Medicine

“Margot’s unparalleled experience in the manufacturing and development of cell-based therapies, and her success building organizations from the ground up strengthen our ability to realize the enormous potential of our pipeline,” Vinny Jindal, Secretome Therapeutics’ president and CEO, said in a statement. “In addition, our CAB includes preeminent physicians who are among the foremost thought leaders in the field of heart failure. Their guidance will be invaluable as we move STM-01 into clinical studies for HFpEF and dilated cardiomyopathy.”

Connor brings more that 30 years of experience in the healthcare and life science industries, and has executive level expertise in leadership, business growth, operational execution, corporate development, strategic planning, and M&A.

Most recently, she was CEO and board member of RoosterBio Inc., where she joined as a founding team member in 2015 and led multiple rounds of investment funding.

During her career, Connor has been involved in more 20 M&A transactions valued at over $1 billion. She has held various senior leadership roles at companies including Lonza, Unilever, FMC, and Chr. Hansen.

Secretome Therapeutics is developing a platform of first-in-class therapeutics derived from neonatal mesenchymal stem cells (nMSC) for the treatment of underserved diseases.

Its lead product, STM-01, is in development for adult and pediatric forms of heart failure, and the company’s pipeline includes novel secretomes for neurodegenerative and dermatological diseases.

Get on the list.
Dallas Innovates, every day.

R E A D N E X T

ReCode Therapeutics Announces Scientific Advisory Board, New Scientific Adviser
The advisers will work closely with management to support ReCode's expansion of its targeted-delivery genetics medicines platform and advance its pipeline of mRNA and gene correction therapeutics.
ReCode Therapeutics Appoints New Member to Board of Director
Dallas-based life science company ReCode Therapeutics has appointed Patricia "Trisha" Millican to its board of directors, bringing with her more than 20 years of experience in the life science industry. ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer and a board member of ReCode Therapeutics, says Millcan brings "decades of proven strategic financial leadership and extensive biopharmaceutical industry experience to ReCode, an ideal complement to the existing makeup of our Board members." The CEO says the company looks forward…
MCE Systems Adds Former GM Mobility, IoT and AI at Microsoft to Advisory Board
Israel-based MCE Systems Ltd., which has a North American office in Dallas, has appointed Jim Hudak, a former senior Microsoft exec with a focus on mobility, IoT, and AI at Microsoft, to the MCE advisory board. MCE is a global leader in digital device lifecycle management (dDLM) for mobile and IoT devices. "Jim is a consummate professional whose keen insight into AI and business will help lead MCE as it grows strategically,” Yuval Blumental, MCE co-founder and CEO said in a statement. “We really see Jim’s capabilities in developing revenue-accelerating partnerships and advising MCE on key expansion areas. By appointing…
Public-Private Consortium Will Fund 3 Gene Therapy Clinical Trials at UT Southwestern
"There are over 10,000 rare diseases that affect millions of people worldwide, and most of them are genetic," notes UT Southwestern's Steven Gray (above, with Susan Iannaccone, M.D.). Testing on a total of eight genetic diseases has been approved for funding by the Bespoke Gene Therapy Consortium and other organizations.
UT Southwestern Names New Chair of President's Advisory Board
UT Southwestern Medical Center announced that Dallas business consultant, attorney, and investor Debra Hunter Johnson, founder of Reciprocity Consulting Group, will chair its President’s Advisory Board for the 2023-2025 term. The board provides Daniel K. Podolsky, M.D., president of UT Southwestern, and top executives with guidance on advancing UT Southwestern’s institutional missions and ambitious agenda, the school said. “We are grateful for Debra’s leadership, insight, and counsel in this vital role as UT Southwestern continues to broaden its capacity to improve medical science while meeting the health care needs of our community, Texas, and beyond,” Podolsky, who holds the Philip…